PRNewsWire
22 Jul 2026, 18:35 UTC · 9w ago
Verdict
Headline takes no side. We score PEN +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The THUNDER study demonstrated that the THUNDERBOLT system achieved an 87.5% successful reperfusion rate in stroke patients with emergent large vessel occlusion.
So whatHigh efficacy rates in clinical trials for a core product typically drive revenue growth and increase market share.
More positive than 93% of claims this week
The THUNDERBOLT system has recently received U.S. FDA clearance and the CE Mark.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 87% of claims this week
THUNDERBOLT is the first and only computer assisted vacuum thrombectomy (CAVT) device for stroke to demonstrate these revascularization and safety rates.
More positive than 79% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company announced successful clinical study results demonstrating the safety and effectiveness of its THUNDERBOLT system for stroke care.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
17h ago
+0.5%
Price flat so far
$318.89 vs $317.39 close before publication (Jul 21) · not market-adjusted
PEN chart →
